Last updated on April 2019

A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies

Brief description of study

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with advanced malignancies.

This investigational intervention treatment uses a single biological drug and is conducted in two parts.

  • Part 1: INCAGN02390 at the protocol-defined starting dose administered every 2 weeks (Q2W), with dose escalation to determine the maximum tolerated dose or pharmacologically active dose. 
  • Part 2: INCAGN02390 administered Q2W or Q4W at the recommended dose(s) from Part 1.


Clinical Study Identifier: TX218264

Find a site near you

Start Over